Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice

Hypertension Research

Volumn 35, Issue 3, 2012, Pages 287-294

  Ohtani, Keisuke ^a   Usui, Soichiro ^a   Kaneko, Shuichi ^a   Takashima, Shin Ichiro ^a   Kitano, Katsunori ^a   Yamamoto, Kanako ^a   Okajima, Masaki ^a   Furusho, Hiroshi ^a   Takamura, Masayuki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

aldosterone; calcium channel blocker; ischemia reperfusion; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALDOSTERONE; BENIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CORONARY REPERFUSION; DISEASE MARKER; DNA DAMAGE; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HORMONE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY;

ALDOSTERONE; ANIMALS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HEMODYNAMICS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84863406642     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.183     Document Type: Article

References (38)

1. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-2098. (Pubitemid 28016233)
2. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985; 76: 1713-1719. (Pubitemid 16196036)
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
4. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med 2000; 109: 315-323.
5. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
7. Schmidt K, Tissier R, Ghaleh B, Drogies T, Felix SB, Krieg T. Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur Heart J 2010; 31: 1655-1662.
8. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin i/angiotensin ii conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597. (Pubitemid 30094728)
9. Hoshide S, Kario K, Mitsuhashi T, Ikeda U, Shimada K. Is there any difference between intermediate-acting and long-acting calcium antagonists in diurnal blood pressure and autonomic nervous activity in hypertensive coronary artery disease patients? Hypertens Res 2000; 23: 7-14. (Pubitemid 30076815)
10. Ogihara T, MatsuzakiM, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, Umemoto S, Kamiya A, Suzuki N, Kumagai H, Ohashi Y, Takishita S, Abe K, Saruta T. The combination therapy of hypertension to prevent cardiovascular events (cope) trial: Rationale and design. Hypertens Res 2005; 28: 331-338. (Pubitemid 40895055)
11. Asanuma H, Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Tada M, Kuzuya T, Hori M. Benidipine, a long-acting ca channel blocker, limits infarct size via bradykinin-and no-dependent mechanisms in canine hearts. Cardiovasc Drugs Ther 2001; 15: 225-231. (Pubitemid 33010605)
12. Wang N, Minatoguchi S, Chen XH, Arai M, Uno Y, Lu C, Misao Y, Nagai H, Takemura G, Fujiwara H. Benidipine reduces myocardial infarct size involving reduction of hydroxyl radicals and production of protein kinase c-dependent nitric oxide in rabbits. J Cardiovasc Pharmacol 2004; 43: 747-757. (Pubitemid 38679595)
13. Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, Kusaka H, Matsubara M. Blockade of t-type voltage-dependent ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line nci-h295r. Eur J Pharmacol 2008; 584: 424-434.
14. Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, Hirano K, Usui S, Wang F, Du W, Yoshioka K, Banno Y, Sasaki M, Ichi I, Okamura M, Sugimoto N, Mizugishi K, Nakanuma Y, Ishii I, Takamura M, Kaneko S, Kojo S, Satouchi K, Mitumori K, Chun J, Takuwa Y. S1p3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 2010; 85: 484-493.
15. Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S. Renoprotective effects of benidipine in combination with angiotensin ii type 1 receptor blocker in hypertensive dahl rats. Hypertens Res 2003; 26: 635-641. (Pubitemid 37086636)
16. Yamashita T, Kawashima S, Ozaki M, Rikitake Y, Hirase T, Inoue N, Hirata K, Yokoyama M. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens 2001; 19: 451-458. (Pubitemid 32195381)
17. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76. (Pubitemid 36859043)
18. Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M. Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. Hypertension 2008; 51: 528-533. (Pubitemid 351156443)
19. Brem AS, Morris DJ, Ge Y, Dworkin LD, Tolbert E, Gong R. Direct fibrogenic effects of aldosterone on normotensive kidney: An effect modified by 11{beta}-hsd activity. Am J Physiol Renal Physiol 2010; 298: F1178-F1187.
20. Makhanova N, Lee G, Takahashi N, Sequeira Lopez ML, Gomez RA, Kim HS, Smithies O. Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol 2006; 290: F61-F69.
21. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Nako H, Ogawa H, Kim-Mitsuyama S. Benidipine, a dihydropyridine l-type/t-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats. J Hypertens 2010; 28: 1321-1329.
22. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005; 115: 1666-1674. (Pubitemid 40814676)
23. Roy D, Floyd RA, Liehr JG. Elevated 8-hydroxydeoxyguanosine levels in DNA of diethylstilbestrol-treated syrian hamsters: Covalent DNA damage by free radicals generated by redox cycling of diethylstilbestrol. Cancer Res 1991; 51: 3882-3885.
24. Liu HR, Gao F, Tao L, Yan WL, Gao E, Christopher TA, Lopez BL, Hu A, Ma XL. Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. Br J Pharmacol 2004; 142: 627-634. (Pubitemid 38969657)
25. Matsubara M, Akizuki O, Ikeda J, Saeki K, Yao K, Sasaki K. Benidipine, an antihypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 2008; 580: 201-213.
26. Cordis GA, Maulik G, Bagchi D, Riedel W, Das DK. Detection of oxidative DNA damage to ischemic reperfused rat hearts by 8-hydroxydeoxyguanosine formation. J Mol Cell Cardiol 1998; 30: 1939-1944. (Pubitemid 28495320)
27. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97: 4F-12F.
28. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4e-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838. (Pubitemid 37296092)
29. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111: 420-427. (Pubitemid 40204425)
30. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-677.
31. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD, Valencik ML, Burnett Jr JC, Redfield MM. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via 00Nongenomic effects00 . Circulation 2010; 122: 370-378.
32. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol 1988; 50: 409-426. (Pubitemid 18088113)
33. Denner K, Doehmer J, Bernhardt R. Cloning of cyp11b1 and cyp11b2 from normal human adrenal and their functional expression in cos-7 and v79 chinese hamster cells. Endocr Res 1995; 21: 443-448.
34. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000; 36: 495-500.
35. Ye P, Kenyon CJ, MacKenzie SM, Jong AS, Miller C, Gray GA, Wallace A, Ryding AS, Mullins JJ, McBride MW, Graham D, Fraser R, Connell JM, Davies E. The aldosterone synthase (cyp11b2) and 11beta-hydroxylase (cyp11b1) genes are not expressed in the rat heart. Endocrinology 2005; 146: 5287-5293. (Pubitemid 41653041)
36. Griendling KK, Sorescu D, Ushio-Fukai M. Nad(p)h oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501. (Pubitemid 30165039)
37. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin ii-induced interstitial cardiac fibrosis via a nox2-containing nadph oxidase. FASEB J 2006; 20: 1546-1548.
38. Yao K, Sato H, Sonoda R, Ina Y, Suzuki K, Ohno T. Effects of benidipine and candesartan on kidney and vascular function in hypertensive dahl rats. Hypertens Res 2003; 26: 569-576. (Pubitemid 36975000)